Navigation Links
How DDT metabolite disrupts breast cancer cells
Date:2/13/2008

Research has shown that the main metabolite of the insecticide DDT could be associated with aggressive breast cancer tumours, but there has been no explanation for this observation to date. Now a report published in the open access journal Breast Cancer Research shows how DDT could act to disrupt hormone-sensitive breast cancer cells.

Michel Aube and colleagues from Universite Laval and Institut national de sante publique in Quebec, Canada have published findings suggesting that DDT's main metabolite, 1,1-dichloro-2,2-bis(p-chlorophenyl)ethylene (p,pi'-DDE), could increase breast cancer progression. They suggest a mechanism whereby p,p'-DDE opposes the androgen signalling pathway that inhibits growth in hormone-responsive breast cancer cells.

The team tested the effect of p,p'-DDE on the proliferation of CAMA-1 cells, a human breast cancer cell line that expresses the estrogen receptor alpha (ERa) and the androgen receptor (AR), either with or without physiological concentrations of estrogens and androgens. They also assessed p,p'-DDE-induced modifications in cell cycle entry and the expression of sex-steroid dependent genes including ESR1 and CCND1, the latter coding for a key protein involved in cell proliferation.

When estrogens and androgens were present in the cell culture medium, increasing concentrations of p,p'-DDE accelerated the growth of CAMA-1 breast cancer cells. p,p'-DDE had a similar effect on the proliferation of MCF7-AR1 cells, an estrogen responsive cell line genetically engineered to over express the AR. Adding the potent androgen dihydrotestosterone together with estradiol to the cell culture medium decreased the recruitment of CAMA-1 cells in the S phase and the expression of ESR1 and CCND1, by comparison with cells treated with estradiol alone. These androgen-mediated effects were blocked with similar efficacy by p,p'-DDE and the potent antiandrogen hydroxyflutamide.

'Our results suggest that in addition to estrogenic compounds, which have been the main focus of researchers over the past decades, chemicals that block the AR could favour breast cancer progression' says Pierre Ayotte, who is leading the research team.

Ayotte's team had previously linked concentrations of p,p'-DDE with tumour aggressiveness in women with breast cancer. They are now investigating the effect on breast cancer cell proliferation of a complex mixture of environmental chemicals, similar to that found in the blood of women, which comprises compounds with estrogenic and antiandrogenic activities.


'/>"/>

Contact: Charlotte Webber
press@biomedcentral.com
44-020-763-19980
BioMed Central
Source:Eurekalert

Related medicine news :

1. Nicotine in breast milk disrupts infants sleep patterns
2. Antibacterial chemical disrupts hormone activities
3. Survival differences by race most apparent in advanced stages of breast cancer
4. MRI finds breast cancer before it becomes dangerous
5. Pathway links inflammation, angiogenesis and breast cancer
6. Drop in breast cancer incidence linked to hormone use, not mammograms
7. Breast cancer prevention practices vary across Canada
8. Eating junk food whilst pregnant and breastfeeding may lead to obese offspring
9. Acrylamide Wont Raise Breast Cancer Risk
10. New link between estrogen and breast cancer
11. Hypnosis Eases Pain of Breast Cancer Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... The American ... to become its next President and Chief Executive Officer, succeeding Dr. James C. Puffer ... Elect beginning July 1, 2018 until Dr. Puffer’s retirement at the end of 2018. ...
(Date:10/13/2017)... ... ... Lori R. Somekh, founder of the Law Office of Somekh & ... and special needs planning attorneys. “Membership in ElderCounsel helps our office remain up to ... with elder law attorneys nationwide,” said Somekh. , ElderCounsel was founded ...
(Date:10/13/2017)... ... ... Ellevate Network, the leading network for professional women, brought together some of ... their inaugural Summit in New York City in June. The event was livestreamed with ... 3 million. To watch the Mobilize Women video, click here . , ...
(Date:10/13/2017)... ... 2017 , ... Coveros, a leader in agile coaching services ... by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile Transformation ... Agile methodologies in a consistent and high value manner across CMS programs. Coveros ...
(Date:10/12/2017)... San Francisco, CA (PRWEB) , ... October 12, ... ... and Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus ... sleep apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... R.I. , Sept. 25, 2017  EpiVax, ... assessment, vaccine design, and immune-engineering today announced the ... on the development of personalized therapeutic cancer vaccines. ... has provided exclusive access to enabling technologies to ... Eng., MBA will lead EpiVax Oncology as Chief ...
(Date:9/19/2017)... Mich. , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company ... destruction of targeted tissues, announced three leadership team developments today:   ... PhD ... ... Veteran medical device executive Josh ...
(Date:9/13/2017)... ATLANTA , Sept. 13, 2017   OrthoAtlanta ... to the Atlanta Football Host Committee (AFHC) for the 2018 ... Monday, Jan. 8, 2018, at Mercedes-Benz Stadium in ... part of the AFHC "I,m In" campaign, participating in many ... ...
Breaking Medicine Technology: